<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323750</url>
  </required_header>
  <id_info>
    <org_study_id>TransitionCHF</org_study_id>
    <nct_id>NCT02323750</nct_id>
  </id_info>
  <brief_title>TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study</brief_title>
  <official_title>Systolic Dysfunction to Congestive Heart Failure Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Göttingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TransitionCHF aims to recruit a unique cohort of patients with asymptomatic left ventricular&#xD;
      dysfunction (NYHA I) to study the progression to symptomatic (&gt;NYHA I) HF and to identify&#xD;
      parameters/ biomarkers promoting and predicting the individual risk of transition. Results&#xD;
      from TransitionCHF Cohort Study will inform and refine current treatment guidelines. The&#xD;
      implementation of common patient data sets and biobanking standards will enable data and&#xD;
      biomaterial sharing with other DZHK study groups. This study will set the standard for a&#xD;
      unique DZHK heart failure database and Biobank for innovative preclinical and clinical&#xD;
      trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>composite endpoint of hospitalization for heart failure and cardiovascular death</measure>
    <time_frame>5 Years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Systolic Dysfunction, Transition, Heart Failure, Biobank</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The DZHK TransitionCHF Cohort Study will include patients with systolic dysfunction (NYHA&#xD;
        I), i.e. (1) patients without a history of HF symptoms and (2) patients who reversed from&#xD;
        symptomatic HF. Patients will be recruited prospectively at the seven participating DZHK&#xD;
        centres and eight external partners from the ALKK network (German Working Group of Leading&#xD;
        Hospital-based Cardiologists) and university hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Asymptomatic systolic dysfunction (defined as: ejection fraction &lt; 40% by&#xD;
             echocardiography or MRI; documented within the last 3 months prior to baseline visit)&#xD;
&#xD;
          -  No history of hospitalization for heart failure (defined as hospitalisation with&#xD;
             symptoms of heart failure requiring initiation of therapy with a loop diuretic or&#xD;
             escalation of a pre-existing loop diuretic therapy within 48 hours after hospital&#xD;
             admission)&#xD;
&#xD;
          -  No heart failure symptoms (NYHA II, III or IV) upon inclusion&#xD;
&#xD;
          -  6MWD ≥ 80% of reference values&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic heart failure (NYHA&gt;I) at baseline visit&#xD;
&#xD;
          -  Any significant valvular disease (&gt; 2nd degree)&#xD;
&#xD;
          -  Severe pulmonary disease (e. g. FEV1 &lt; 70% of normal limit)&#xD;
&#xD;
          -  Severe renal disease (GFR &lt; 15 ml/min)&#xD;
&#xD;
          -  ejection fraction at baseline visit ≥ 50% by echocardiography or MRI&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Pericardial disease&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Myocardial infarction within the last 3 months&#xD;
&#xD;
          -  Planned cardiac surgical intervention within 3 months after inclusion&#xD;
&#xD;
          -  Geographical reasons (e. g. patients living outside Germany or planning to move&#xD;
             abroad)&#xD;
&#xD;
          -  Inability to give informed consent (e. g. mental disorders)&#xD;
&#xD;
          -  Therapy with loop diuretics (e. g. torasemide, furosemide, piretanide)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerd Hasenfuß, Prof</last_name>
    <phone>49-551-39-20400</phone>
    <email>rfaber@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Edelmann, Dr</last_name>
    <phone>49-551-39-22658</phone>
    <email>fedelmann@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Edelmann, Dr</last_name>
      <phone>49-551-39-22658</phone>
      <email>fedelmann@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Göttingen</investigator_affiliation>
    <investigator_full_name>Gerd Hasenfus</investigator_full_name>
    <investigator_title>Prof. Dr. med. Gerd Hasenfuß</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

